Abstract:The aim of this study was to determine, in a Phase I/II clinical trial, the pharmacokinetics, dosimetry and toxicity, as well as antitumor activity, of the I-131-labeled murine anti-carcinoembryonic antigen (CEA) monoclonal antibody, NP-4 (IgG(1) subtype). Methods: A total of 57 patients with CEA-expressing tumors (29 colorectal, 9 lung, 7 pancreas, 6 breast and 4 medullary thyroid cancer patients), mostly in very advanced stages, were treated. The patients underwent a diagnostic study (1-3 mg of IgG and 8-30 mCi of I-131) to assess tumor targeting and to estimate dosimetry, followed by the therapeutic dose (4-23 mg and 44-268 mCi), based on the radiation dose to the red marrow. Imaging was performed from 4-240 hr postinjection (planar and SPECT). Blood and whole-body clearance were determined; radiation doses were calculated by the Medical Internal Radiation Dose scheme. Results: Red marrow doses ranged from 45 to 706 cGy, and whole-body doses ranged from 31 to 344 cGy. Differences in pharmacokinetics were found between different types of CEA-producing tumors: blood T-1/2 was significantly lower in colorectal cancer when compared to all other tumor types (21.4 +/- 11.1 hr versus 35.8 +/- 13.2 hr; p < 0.01), as was also whole-body t(1/2). Myelotoxicity was dose-limiting, and its severity was related to the types of prior therapy and extent of bone marrow involvement. In patients without prior radiation or chemotherapy, marrow doses as high as 600 cGy were tolerated without evidence of dose-limiting toxicity. No major toxicity to other organs was observed. Tumor doses were inversely related to the tumor mass and ranged between 2 and 218 cGy/mCi. Modest antitumor effects were seen in 12 of 35 assessable patients (1 partial remission, 4 minor/mixed responses and 7 with stabilization of previously rapidly progressing disease). Conclusion: These results suggest that prior chemotherapy or external beam radiation is an important risk factor for the development oi hematological toxicity in radioimmunotherapy and that higher radiation doses may be delivered to tumors of patients without prior therapy compromising the bone marrow reserve. The different and, in the individual cases, unpredictable clearance rates suggest the necessity of dosimetry-based treatment planning rather than mCi/m(2) dosing. Small tumors seem to be more suitable for radioimmunotherapy because of their favorable dosimetry, but to achieve better therapeutic results in patients with bulky disease, the application of higher, potentially myeloablative doses is indicated.

Radioimmunotherapy of Human Colon Cancer Xenografts with<sup>131</sup>I-Labeled Anti-CEA Monoclonal Antibody

Radioimmunotherapy Of Human Colon Cancer Xenografts With I-131-Labeled Anti-Cea Monoclonal Antibody

Radioimmunotherapy of human colon cancer xenografts with 131I-labeled anti-CEA monoclonal antibody.

Radioimmunotherapy of human colon cancer xenografts by using {sup 131}I labeled-CAb{sub 1} F(ab'){sub 2}

Radioimmunotherapy of human colon cancer xenografts by using 131I labeled-CAb1 F(ab')2.

Local Radioimmunotherapy of Breast Cancer-Bearing Nude Mice Using Anti-Cea Monoclonal Antibody C50 Labeled with 131I

Radioimmunoimaging and Biodistribution of ~(131)I Labeled Anti-Cea Monoclonal Antibody C50 in Nude Mice Bearing Human Breast Carcinoma Xenografts

Evaluation of Therapeutic Effectiveness Of131i-Antiegfr-bsa-pcl in a Mouse Model of Colorectal Cancer

Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.

[Influence of Combination of Low Dosage 131I-Labeled Anti-Carcinoembryonic Antigen Antibody C50 and 5-Fluorouracil on Tumor Growth of Colorectal Cancer Xenografts in Nude Mice].

Clinical Application of Radioimmunoguided Surgery in Colorectal Cancer Using125i-Labeled Carcinoembryonic Antigen-Specific Monoclonal Antibody Submucosally

Radioimmunolocalization and blodistribution of 131Ⅰ labeled anti-CEA,TPS and mixture monoclonal antibody in nude mice bearing human breast cancer xenografts

Induction of Tumor Cell Apoptosis in Colorectal Cancer Xenografts of Nude Mice with Low Dosage of ~(131) I-labelled Anti-Carcinoembryonic Antigen Antibody C50 Combined with Chemotherapy

Fractionated Radioimmunotherapy Using Low Doses of Iodine-131 Labeled Anti-Cea Monoclonal Antibody after Tumor Volume Reduction.

Biodistribution of 131I-Anti-cea Monoclonal Antibody (C50) in Nude Mice Model and Patients of Colon Cancer

Evaluation of the internal therapeutic effectiveness of 131I-antiEGFR-BSA-PCL in nude mice with colorectal cancer

Localization and Tumor Growth Inhibition of I-131-Labeled Monoclonal Antibody ERIC1 in a Subcutaneous Xenograft Model of Small Cell Lung Cancer in SCID Mice

Radioimmunoimaging and Targeting Treatment in an Immunocompetent Murine Model of Triple-Negative Breast Cancer Using Radiolabeled Anti-Programmed Death-Ligand 1 Monoclonal Antibody

The Synergetic Effect of 188Re-Anti-cea-mcab and Interleukin 12 Gene in Colon Cancer Therapy

Radioiodination, Purification, and Evaluation of Antihuman Tumor-Derived Immunoglobulin G Light Chain Monoclonal Antibody in Tumor-Bearing Nude Mice.

Radioimmunoguided Surgery of Colorectal Cancer by ~(125)I-Labeled Monoclonal Antibody CL58